Krebs Biochemicals & Industries Valuation

Is KREBSBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KREBSBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KREBSBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KREBSBIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KREBSBIO?

Key metric: As KREBSBIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KREBSBIO. This is calculated by dividing KREBSBIO's market cap by their current revenue.
What is KREBSBIO's PS Ratio?
PS Ratio	3.5x
Sales	₹506.94m
Market Cap	₹1.78b

KREBSBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.6x
Enterprise Value/EBITDA	-37.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does KREBSBIO's PS Ratio compare to its peers?

The above table shows the PS ratio for KREBSBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.4x
QUESTLAB Quest Laboratories	2.2x	n/a	₹1.8b
532637 Mangalam Drugs & Organics	0.5x	n/a	₹1.7b
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	₹1.6b
532384 Tyche Industries	2.8x	n/a	₹2.0b
KREBSBIO Krebs Biochemicals & Industries	3.5x	n/a	₹1.8b

Price-To-Sales vs Peers: KREBSBIO is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.4x).

Price to Sales Ratio vs Industry

How does KREBSBIO's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$89.20m
539561 Remedium Lifecare	0.07x	n/a	US$28.41m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.04m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.22m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: KREBSBIO is expensive based on its Price-To-Sales Ratio (3.5x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is KREBSBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KREBSBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate KREBSBIO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

-8.8%

33.1%